Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-15-003597
Filing Date
2015-05-13
Accepted
2015-05-13 17:03:03
Documents
10
Period of Report
2015-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0315_dandritbio.htm 10-Q 392291
2 CERTIFICATION f10q0315ex31i_dandritbio.htm EX-31.1 8067
3 CERTIFICATION f10q0315ex31ii_dandritbio.htm EX-31.2 8110
4 CERTIFICATION f10q0315ex32i_dandritbio.htm EX-32.1 6023
  Complete submission text file 0001213900-15-003597.txt   3392581

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE pmhs-20150331.xml EX-101.INS 379824
6 XBRL SCHEMA FILE pmhs-20150331.xsd EX-101.SCH 35443
7 XBRL CALCULATION FILE pmhs-20150331_cal.xml EX-101.CAL 44185
8 XBRL DEFINITION FILE pmhs-20150331_def.xml EX-101.DEF 64886
9 XBRL LABEL FILE pmhs-20150331_lab.xml EX-101.LAB 302957
10 XBRL PRESENTATION FILE pmhs-20150331_pre.xml EX-101.PRE 183857
Mailing Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7
Business Address DANDRIT BIOTECH A/S FRUEBJERGVEJ 3 BOX 62 2100 COPENHAGEN G7 45 39179840
DanDrit Biotech USA, Inc. (Filer) CIK: 0001527728 (see all company filings)

EIN.: 452259340 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-54478 | Film No.: 15859166
SIC: 2834 Pharmaceutical Preparations